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LETTERS
First Shiga 
Toxin-Producing 
Escherichia coli 
Isolate from a 
Patient with 
Hemolytic Uremic 
Syndrome, Brazil
To the Editor: Infection by Shiga
toxin (Stx)-producing Escherichia coli
(STEC), particularly strains of sero-
type O157:H7, can cause sporadic
cases and outbreaks of diarrhea, hem-
orrhagic colitis (HC), and hemolytic
uremic syndrome (HUS) (1). Some
other serotypes (e.g., O26:H11,
O111:H8, O111:NM, and O113:H21)
share a similar pathogenic potential.
STEC are distributed worldwide, but
most of the HC and HUS cases were
reported from industrialized nations of
the Northern and Southern Hemi-
spheres (2). In South America, HUS is
a major cause of acute renal failure in
infants in Argentina (3) and Chile (4).
However, in Brazil human STEC
infections have been restricted to spo-
radic cases of nonbloody diarrhea
(5,6). Although a high frequency of
STEC strains was recently found in
foods and animal reservoirs (7,8), only
some of the serotypes identified in
animals (8) were recognized as causes
of human illness (e.g., O157:H7,
O22:H16, O82:H8, and NT:H21).
Moreover, there is currently no nation-
wide surveillance system for HUS in
Brazil, and STEC-associated HUS has
not been previously reported in our
country. 
We describe the case of an 8-
month-old boy from a northeastern
state in Brazil, who was admitted to
the emergency room of Hospital São
Paulo, São Paulo, on March 17, 2001;
the boy had anemia, oliguria, and
edema of lower extremities. He had an
acute diarrheal prodromal illness 3
weeks before hospital admission. On
the same day as admission, respiratory
failure developed, and the child was
transferred to the pediatric intensive-
care unit of the hospital. The boy had
hemolytic anemia (hemoglobin level
11.9 g/dL at admission, and 9.1 g/dL
several days later), renal failure (blood
urea nitrogen 43.8 mg/dL and serum
creatinine 1.5 mg/dL), and thromb-
ocytopenia (platelet count of 70,000/
mm3), leading to a diagnosis of HUS.
The patient received treatment with
fresh frozen plasma and needed renal
support (peritoneal dialysis) for 7
days. Once renal function was reestab-
lished, the patient’s outcome was
good.
Feces were collected as soon as
HUS was suspected and plated onto
MacConkey Sorbitol Agar (Difco,
Becton Dickinson Microbiology Sys-
tems, Sparks, MD). Only sorbitol-pos-
itive colonies grew and were
biochemically identified as E. coli by
standard procedures. The E. coli iso-
lates expressed Stx1, as identified by
cytotoxicity and neutralization assays
on Vero cells (5). Presence of stx1 and
intimin (eae) gene sequences was con-
firmed by polymerase chain reaction
(9,10). The E. coli strain belonged to
serotype O26:H11 and produced
enterohemorragic  E. coli hemolysin
(enterohemolysin).
This report is the first on the isola-
tion of an STEC strain in a HUS
patient in Brazil. The serotype
O26:H11 has been described as an
agent of HC and HUS in other coun-
tries and was the second most frequent
serotype found in STEC strains iso-
lated from diarrheal cases in our set-
tings (6). Moreover, expression of
Stx1 and enterohemolysin and the
presence of eae are virulent character-
istics usually found in the human
STEC strains isolated so far in Brazil.
These findings show the importance
of looking for non-O157 STEC strains
besides O157:H7 in patients with HC
and HUS in Brazil. Surveillance for
HUS, either nationally or in sentinel
population-based studies, should be
performed in Brazil, and studies on the
occurrence of HUS and its association
with STEC infections are under inves-
tigation in our laboratory.
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Emergence of 
Vancomycin-
Intermediate 
Staphylococcus 
aureus and 
S. sciuri, Greece
To the Editor: Staphylococcal
isolates with reduced susceptibility to
glycopeptides, such as vancomycin
and teicoplanin, are a serious public
health problem because staphylococci
frequently show multidrug resistance,
and glycopeptides are the only
remaining effective drugs. Since the
early reports of glycopeptide-resistant
staphylococci, teicoplanin resistance
has become more common than van-
comycin resistance, particularly
among coagulase-negative staphylo-
coccal species (1-3). In cases of sta-
phylococci with reduced susceptibility
to vancomycin (vancomycin-interme-
diate staphylococci), an increasing
number of strains showing heterore-
sistance are reported (strains that con-
tain subpopulations of cells at
frequencies >10-6 for which the van-
comycin MICs are 8 µg/mL to 16 µg/
mL); homogeneous resistance still
appears to be rare (2,4-7). In northern
Greece, resistance to teicoplanin has
recently been documented in S.
haemolyticus  strains isolated from
clinical infections (8). We report the
first bloodstream infections in Greece
associated with S. aureus and S. sciuri
strains that have homogeneous inter-
mediate-resistance to vancomycin
(MIC = 8 µg/mL). 
In our department, all clinically
significant staphylococcal isolates are
screened for reduced susceptibility to
vancomycin and teicoplanin by an
agar incorporation method (9), which
has been routinely performed since
January 1999. An inoculum of 104
CFU/spot from a log-phase broth cul-
ture was spread on Mueller-Hinton
agar plates containing appropriate
antibiotic concentrations. The strains
were incubated for a full 24 hours
before the MICs were read. When a
reduced susceptibility to vancomycin
was observed (MIC 8 to 16 µg/mL),
the test was repeated for confirmation
of the result and the strains were also
tested by National Committee for
Clinical Laboratory Standards
(NCCLS) broth microdilution (9) and
E-test (AB Biodisk, Solna, Sweden)
with BHI agar (Oxoid, Ltd., Basing-
stoke, Hampshire, UK) and an inocu-
lum density adjusted to 0.5 McFarland
value. S. aureus ATCC 29213, which
had MICs for vancomycin of 1 µg/mL
and for teicoplanin of 0.5 µg/mL, was
used as a control for the estimation of
the MICs. Two vancomycin-interme-
diate staphylococcal isolates (one S.
aureus and one S. sciuri) were recov-
ered in our hospital during December
2000 and April 2001, respectively.
The organisms were identified with
the Vitek system (bioMerieux Vitek,
La Balme les Grottes, France). Slide-
coagulase test and Staph ID 32 API
system (API system, bioMerieux) con-
firmed identification. Susceptibility to
18 antimicrobial agents was evaluated
with the Vitek system according to the
recommendations of the manufacturer,
and carriage of the mecA gene was
confirmed with a polymerase chain
reaction (PCR) that amplifies a 449-bp
product.
The first strain (S. aureus) was
recovered from a 52-year-old man
who was hospitalized after a severe
traffic accident. The patient had multi-
ple injuries, including an external
laryngeal trauma, pelvic ring disrup-
tion, and various fractures of the
extremities. He underwent immediate
tracheotomy, and a neurosurgical
operation was performed to evacuate
an extracerebral hematoma. Ceftazi-
dime, clindamycin, ciprofloxacin,
metronidazole, teicoplanin, and van-
comycin were periodically adminis-
tered as prophylaxis. An oxacillin-
resistant S. aureus isolate was recov-
ered from two blood cultures 4 weeks
after the patient’s admission. The
strain was also resistant to tobramycin,
macrolides, tetracyclines, rifampicin,
and fusidic acid, and had intermediate
resistance to vancomycin (MIC 8 µg/
mL) and teicoplanin (MIC 16 µg/mL)
by all tested methods (agar dilution,
broth microdilution, and E-test). The
strain was susceptible to chloram-
phenicol, cotrimoxazole, fosfomycin,
gentamicin, kanamycin, nitrofuran-
toin, and ofloxacin. The removal of an
intravenous catheter and treatment
with gentamicin and vancomycin
eradicated the infection. 
The second strain (S. sciuri) was
recovered from a 35-year-old man
who was an intravenous drug user. He
was admitted with renal failure, elec-
trolyte disturbances, and acute respira-
tory distress, which necessitated
intubation and mechanical ventila-
tion. The patient became febrile, and
multiple courses of antibiotics (amika-
cin, cefepime, ciprofloxacin, metron-
idazole, and vancomycin, alone or in
combinations) were administered
before the S. sciuri strain was isolated.
Seven weeks after his admission, an
oxacillin-resistant S. scuiri strain that
had cross-resistance to aminoglyco-
sides, macrolides, quinolones,
rifampicin, and tetracycline was found
in subsequent blood cultures. The
MIC of the strain for vancomycin was
8 µg/mL and for teicoplanin 16 µg/mL
by the agar dilution method, and the
result was confirmed by the E-test and
the broth microdilution method. The
strain was susceptible only to cotri-
moxazole, fosfomycin, and nitrofuran-
toin. The patient improved clinically
and was subsequently discharged
on cotrimoxazole and vancomycin
therapy. 